[Long-term treatment of hyperlipoproteinemia with etofibrate].
In the treatment of hyperlipoproteinemia, longterm results are of particular interest. Fifty-five patients with mixed hyperlipidemia, who had been treated with Etofibrat in a controlled clinical trial, underwent a follow-up examination one year after conclusion of the study, and data of current lipid treatment and lipid status were recorded. Also investigated were the compliance and motivation of the patients. Within the course of the clinical study, patients with combined hyperlipidemia showed a marked decrease in cholesterol levels of 21%, and of triglycerides of 38%. At the end of the trial, 20 patients continued to receive Etofibrat. Under this treatment, the lowered cholesterol and triglyceride levels were maintained, while in patients receiving other lipid-lowering agents, the triglycerides rose again, and patients not receiving any further medication showed an increase in both triglyceride and cholesterol levels.
Bartz
V T
VT
Gatz
J
J
Slotty
C
C
Schröter
C
C
Töle
R
R
Wand
P
P
D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D006950:Hyperlipidemia, Familial Combined / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008134:Long-Term Care
D000960:Hypolipidemic Agents; D008055:Lipids; C009746:etofibrate; D002995:Clofibric Acid